Vitamin D deficiency associated with disease progression for patients with HIV

This article is more than 8 years old. Click here for more recent articles on this topic

Vitamin D deficiency is highly prevalent in patients with HIV and is associated with an increased risk of disease progression, investigators from the EuroSIDA cohort report in the online edition of AIDS.

The investigators from Europe, Argentina and Israel found a strong relationship between low levels of the vitamin and an increased risk of all-cause mortality and the development of an AIDS-defining condition. They comment: “vitamin D deficiency therefore represents a new, independent, unfavourable prognostic marker in HIV infection.”

There is a some evidence showing that vitamin D deficiency is linked with a number of serious illnesses in the HIV-negative population, including cancers and heart disease, but the strongest association is between deficiency and bone thinning.

Glossary

disease progression

The worsening of a disease.

AIDS defining condition

Any HIV-related illness included in the list of diagnostic criteria for AIDS, which in the presence of HIV infection result in an AIDS diagnosis. They include opportunistic infections and cancers that are life-threatening in a person with HIV.

absorption

The process (or rate) of a drug or other substances, such as food, entering the blood.

metabolism

The physical and chemical reactions that produce energy for the body. Metabolism also refers to the breakdown of drugs or other substances within the body, which may occur during digestion or elimination.

Levels of the vitamin below 10 nanograms per millilitre (ng/ml) are widely accepted as showing deficiency.

A number of studies have demonstrated that vitamin D deficiency is common in patients with HIV. Possible reasons include low levels of sun exposure, poor absorption, kidney or liver impairment, or the interference of antiretroviral drugs with vitamin D metabolism.

Investigators from the EuroSIDA cohort wished to establish the prevalence of vitamin D deficiency among their patients, its risk factors, and its relationship with disease progression.

A total of 1985 patients were involved in the study. Most of the patients (82%) were taking combination antiretroviral therapy.

Vitamin D levels were assessed on entry to the study, and placed into three categories: low (below 10 ng/ml); medium (10 to 30 ng/ml); and high (above 30 ng/ml).

Results showed that 24% of participants had vitamin D deficiency, 65% had moderate levels of the vitamin, and only 11% had vitamin D levels above 30 ng/ml.

“The present results confirm that vitamin D insufficiency or deficiency is frequent in HIV-infected persons,” comment the investigators.

For statistical reasons, the patients were then stratified into three categories (below 12 ng/m; 12 to 20 ng/ml and above 20 ng/ml).

Factors associated with vitamin D levels in the lowest tertile included black race (p = 0.0006), injecting drug use (p = 0.02), heterosexual HIV risk (p = 0.0001), and older age (p = 0.01).

HIV therapy that included a protease inhibitor was associated with a lower risk of vitamin D deficiency (p = 0.001). The investigators note this finding is “of unclear biological relevance”.

Next, the researchers examined the relationship between vitamin D levels and disease progression.

Five years after baseline, 10% of patients with vitamin D in the lowest tertile had developed AIDS, compared to 6% of individuals in the middle group and 5% of patients with the highest vitamin D levels.

Mortality rates also differed according to vitamin D status, and were highest for patients with vitamin D deficiency (11 vs 7 vs 6%).  Rates of non-AIDS-defining events were 9 vs 7 vs 7%.

Low levels of vitamin D were related to poorer outcomes.

Compared to participants with the lowest levels of vitamin D, people in the middle and upper tertiles had a significantly lower risk of progression to AIDS (p = 0.00086 and p = 0.02 respectively).

Similarly, the risk of death was lower for people in the middle and upper tertiles (p = 0.045 and p = 0.003 respectively).

People with the highest levels of vitamin D were also significantly less likely than those with vitamin levels below 12 ng/ml to die of a non-AIDS-related cause.

Adjustment for CD4 cell count and viral load further confirmed that patients with moderate or high levels of vitamin D had a reduced risk of death (p = 0.025 and p = 0.048 respectively).

“A very low [vitamin] D level was associated with events, even in the case of virologically controlled HIV infection and immune restoration,” the authors emphasise.

They conclude: “These results provide strong evidence that vitamin D deficiency is an important cofactor in HIV disease progression, even in the setting of widespread, efficient cART [combination antiretroviral therapy]. Whether the relationship between vitamin D deficiency and events is casual must now be addressed.”

References

Viard J-P et al. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS 25, online edition: doi: 10.1097/QAD.0b013e328347f6f7, 2011 (click here for the free abstract).